ライフサイエンス出版株式会社

FacebookTwitterInstagram
menu

Japanese Pharmacology & Therapeutics (JPT)

Vol. 42 Suppl. 2 2014

■ SYMPOSIUM

【Symposium 1】

1 How Do We Have to Secure High Reliability of Clinical Trials?

T.Yamazaki

Jpn Pharmacol Ther 2014 42(s2) s66-8


2 How Do We Have to Secure High Quality of Clinical Trials and Research?

Y. Ohashi

Jpn Pharmacol Ther 2014 42(s2) s69-74


【Symposium 2】

1 Prospect of Investigator-initiated Clinical Trials in Japan

T. Miyatai

Jpn Pharmacol Ther 2014 42(s2) s77-7


2 Investigator-initiated Clinical Trials of Bevacizumab fora Ovarian Cancer

N. Katsumata

Jpn Pharmacol Ther 2014 42(s2) s78-81


3 Rituximab for Childhood-onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-dependent Nephrotic Syndrome: An Investigator Initiated, Multicenter, Double-blind, Randomized, Placebe-controlled Trial

K.Iijima

Jpn Pharmacol Ther 2014 42(s2) s82-4


4 From the Position of Contract Research Organizations, Key to Success of Investigator Initiated Clinical Trials

F. Kobayashi

Jpn Pharmacol Ther 2014 42(s2) s85-7


5 Role of Coodinating Office in Investigator Initiated Clinical Trial

M. Kume

Jpn Pharmacol Ther 2014 42(s2) s88-90


【Symposium 3】

1 Management of Conflict of Interest in Investigator-initiated Clinical Research in The University of Tokyo Hospital

Y. Arakawa

Jpn Pharmacol Ther 2014 42(s2) s91-5


2 Management of Investigator-initiated Clinical Trials in the Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

M. Fukutani

Jpn Pharmacol Ther 2014 42(s2) s96-9


3 Points-to-Consider Regarding to Company Funding/Participating/Driving Clinical Researches-Suggestion of the System and Procedures for Risk Prevention

M. Kitagawa

Jpn Pharmacol Ther 2014 42(s2) s100-2


4 Management of Conflict of Interest in Investigator-initiated Clinical Research Regarding to Public Interest Incorporated Foundation

T.Miyazaki

Jpn Pharmacol Ther 2014 42(s2) s103-8

■REVIEW ARTICLE

Utilization of QUADAS-2; a Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies 2 as a Risk of Bias Evaluation Tool

N.Kojimahara, et al.

Jpn Pharmacol Ther 2014 42(s2) s127-34

■ORIGINAL ARTICLE

The Quality Evaluation of Investigator-initiated Clinical Trial Protocols in the University of Tokyo Hospital

M. Goto , et al.

Jpn Pharmacol Ther 2014 42(s2) s135-47

■CASE REPORT

Investigation of the Reporting System for Adverse Drug Reactions and Infections Based on Japanese Pharmaceutical Affairs Law

H. Ikeda, et al.

Jpn Pharmacol Ther 2014 42(s2) s149-53

■CASE REPORT

Questionnaire Survey of Researchers about the Support of Clinical Studies by Clinical Research Coordinators in the Hokkaido University Hospital

M. Deai, et al.

Jpn Pharmacol Ther 2014 42(s2) s154-9